Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - StockTitan
external-link
Bicara Therapeutics: Newly Minted Upsized IPO With Positive Early Data (NASDAQ:BCAX) - Seeking Alpha
external-link
Zenas BioPharma, Bicara Therapeutics sets IPO price ranges as summer lull ends - MarketWatch
external-link
Zenas, Bicara set out to raise $180M-plus in separate IPOs to fund autoimmune, cancer prospects - Fierce Biotech
external-link
Two antibody startups file for IPOs amid summer slump - BioPharma Dive
external-link
31,780 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Bought by Walleye Capital LLC - MarketBeat
external-link
Biotech Startups Make Pre-Election Sprint to the Public Markets - The Wall Street Journal
external-link
Bicara Therapeutics (NASDAQ:BCAX) Sets New 1-Year Low - What's Next? - MarketBeat
external-link
The biggest private biotech investments in December 2023
external-link
Bicara Therapeutics Announces Publication in Cancer Resea...
external-link
Strong Wall Street Debut Shows Potential Of Indian Billionaire-Backed Bicara’s Cancer Drugs - Forbes
external-link
Bicara Chief Executive Officer Claire Mazumdar will present at the Stifel 2024 Healthcare Conference in New York, NY. View the details and access the live webcasts and replays on our website here: htt
external-link
Bicara Therapeutics, Adecoagro, and More Stocks See Action From Activist Investors - Barron's
external-link
BCAX IPO News - Oncology biotech Bicara Therapeutics files for a $200 million IPO - Renaissance Capital
external-link
Bicara Therapeutics (NASDAQ:BCAX) Shares Gap Down - Time to Sell? - MarketBeat
external-link
Zenas, MBX, Bicara head to Nasdaq in hot day for biotech ...
external-link
Bicara, Zenas seek IPOs to push late-phase assets toward ...
external-link
Bicara Therapeutics Expands Management Team with the Appointment of David Raben, M.D., as Chief Medical Officer
external-link
Bicara Therapeutics to Participate in Upcoming March Investor Conferences
external-link
We are excited to share that we have closed our IPO and are listed on Nasdaq as BCAX! This marks an important new chapter for our company as we aim to deliver transformative bifunctional therapies to
external-link
TPG GP A, LLC Acquires New Stake in Bicara Therapeutics Inc - GuruFocus.com
external-link
This cancer drug developer held the Bay State's largest IPO of 2024 - The Business Journals
external-link
Bicara Therapeutics (NASDAQ:BCAX) Sets New 1-Year Low - Should You Sell? - MarketBeat
external-link
Bicara Therapeutics initiated with bullish view at Morgan Stanley, here's why
external-link
Bicara Therapeutics Expands Clinical Team with Appointments of Jeltje Schulten, M.D., MBA, as SVP of Clinical and Medical Affairs and Rita Dalal, MBBS, MPH, as VP of Clinical Development - Yahoo Finan
external-link
Bicara Therapeutics to Host Webinar to Review Latest Clinical Trial Data for BCA101
external-link
With IPO, have the capital and resources for clinical studies: Bicara CEO - The Economic Times
external-link
TPG-backed Bicara Therapeutics raises $315 mln in US IPO - Reuters
external-link
At Bicara, we’re driven by a shared vision to bring first-in-class bifunctional therapies to patients with solid tumors. We believe in the power of #diversity and #inclusion, and we’re building a team
external-link
A Look at an Upcoming IPO in a Quiet Market - Institutional Investor
external-link
Bicara Therapeutics Picks Morgan Stanley For IPO of Up to $150 Million - Bloomberg
external-link
Why Cancer Is The New Cardiology For Hospital Chains
external-link
This morning, we announced our third quarter 2024 financial results and business update, highlighting the strong development progress we have made with ficerafusp alfa and the successful completion of
external-link
Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference
external-link
🔬 Cancer doesn’t wait. Neither does Bicara Therapeutics.
👩⚕️ $BCAX’s mission as a clinical stage biotherapeutic company is clear: to turn groundbreaking discoveries into real, life-altering new can
external-link
North American Startup Funding Weakened In Q3 As Largest Deal Took Longer To Close
external-link
Cidara Therapeutics Completes Enrollment of Phase 2b NAVIGATE Trial Evaluating CD388 for Prevention of Seasonal Influenza
external-link
Bicara Therapeutics closes $362m IPO in flurry of biotech listing activity - Yahoo Finance
external-link
Zenas, Bicara set out to raise $180M-plus in separate IPOs
external-link
Cantor Fitzgerald starts Bicara Therapeutics with Overweight rating - Investing.com
external-link
3 Biotechs Seek Over $700M in Renewed IPO Rush - BioSpace
external-link
Bicara Therapeutics initiated with a Not Rated at Goldman Sachs
external-link
Logo - Bicara Therapeutics Expands Clinical Team with Appointments of Jeltje Schulten, M.D., MBA, as SVP of Clinical ...
external-link
Billionaire-Backed Cancer Researcher Claire Mazumdar Finds Entrepreneurial Niche
external-link
Bicara Therapeutics (NASDAQ:BCAX) Stock Price Down 5.8% - Time to Sell? - MarketBeat
external-link
Bicara raises second $100M+ round of 2023, closing new series C
external-link
Bicara Therapeutics to Present at Upcoming November Investor Conferences
external-link
FDA Clears 23andMe BRCA1/2 Consumer Health Risk Report ...
external-link
Bicara Therapeutics Expands Clinical Team with Appointments of Jeltje Schulten, M.D., MBA, as SVP of Clinical and ...
external-link
Indian biopharma spinout raises second nine-figure round this ...
external-link
Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
external-link
Bicara Therapeutics reports interim data from Phase I/Ib HNSCC treatment trial - Clinical Trials Arena
external-link
Bicara Therapeutics Announces Closing of $362 Million - GlobeNewswire
external-link
Bicara Therapeutics Announces Oversubscribed $165 Million Series C Financing
external-link
Bicara Therapeutics files for a $200 million IPO - The Pharma Letter
external-link
Bicara Therapeutics Rings the Nasdaq Stock Market Opening Bell - Nasdaq
external-link
Bicara Therapeutics raises $362 million in Nasdaq debut - The Pharma Letter
external-link
Bicara Therapeutics Reports Strong IPO and Clinical Advancements - TipRanks
external-link
Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
external-link
BCAX IPO News - Oncology biotech Bicara Therapeutics sets terms for $200 million IPO - Renaissance Capital
external-link
Bicara and Zenas file for IPOs to push late-phase prospects toward finish line - Fierce Biotech
external-link
At Bicara, we are all working towards the same goal - to transform the lives of people living with #cancer. From the evolution of a small, startup biotech, to where we are now as a public company, it’
external-link
Stock Market: खबरों वाले ये शेयर करा सकते हैं आज कमाई, बस बनाए रखें नजर
external-link
We remain steadfast in our mission to transform the treatment of #cancer. With our recent #IPO, we’ve reinforced our commitment to advancing solutions in the fight against this devastating disease. Ou
external-link
Bicara Therapeutics Picks Morgan Stanley For IPO of Up to $150 Million
external-link
Stocks To Watch: Bicara Therapeutics Sees RS Rating Rise To 83 - Investor's Business Daily
external-link
3 Biotech IPOs, $703M Raised for Clinical Trials in Cancer, Immunology & Endocrine Disorders - MedCity News
external-link
BCAX IPO News - Oncology biotech Bicara Therapeutics increases shares offered 25% ahead of $250 million IPO - Renaissance Capital
external-link
Bicara Therapeutics aims for up to $828 mln valuation in U.S. IPO - Reuters
external-link
Three’s a crowd? MBX follows Bicara, Zenas into IPO queue - BioCentury
external-link
Bicara Leads Trio of US Biotech IPOs Raising $703 Million - Bloomberg
external-link
Oncology biotech Bicara unveils IPO pitch same day as Zenas - Endpoints News
external-link
Bicara Therapeutics Appoints Mike Powell, Ph.D., and Christopher Bowden, M.D. to Board - citybiz
external-link
763,943 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Bought by Wellington Management Group LLP - MarketBeat
external-link
Bicara Therapeutics Appoints Lara Meisner as Chief Legal Officer
external-link
Bicara Therapeutics picks Morgan Stanley for IPO of up to $150m.
external-link
Targeted cancer therapy player Bicara Therapeutics raises $165 mn in Series C financing
external-link
Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference - GlobeNewswire
external-link
An exciting moment for our team today as we celebrated becoming a public company by ringing the #OpeningBell at Nasdaq! This moment marks an important new chapter in our journey, reinforcing our commi
external-link
Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference
external-link
Biocon accused of committing IP theft to create cancer biotech Bicara - Fierce Biotech
external-link
BCAX IPO News - Oncology biotech Bicara Therapeutics prices upsized IPO at $18, the high end of the range - Renaissance Capital
external-link
Zenas, MBX and Bicara all head to Nasdaq in hot day for biotech IPOs - Fierce Biotech
external-link
Bicara Therapeutics Expands Board of Directors with Appointments of Mike Powell, Ph.D., and Christopher Bowden, M.D. - Yahoo Finance
external-link
Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
external-link
Bicara Therapeutics Announces Pricing of Upsized Initial Public Offering - GlobeNewswire
external-link
Year in photos: Makers, musicians, faces and places of 2024
external-link
Bicara Therapeutics initiated with a Buy at H.C. Wainwright
external-link
Bicara Therapeutics Reports Updated Interim Phase 1/1b Data of Ficerafusp Alfa (BCA101) in 1L HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) - Business Wire
external-link
Amgen Highlights Positive Phase III Lumakras Data in ...
external-link